(R)-tert-butyl 3-((R)-hydroxy(phenyl)methyl)piperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (R)-tert-butyl 3-((R)-hydroxy(phenyl)methyl)piperidine-1-carboxylate
• 英文别名: tert-butyl (3R)-3-[(R)-hydroxy(phenyl)methyl]piperidine-1-carboxylate
• 化学式: C₁₇H₂₅NO₃
• 分子量: 291.39
• InChiKey: AOHTUMSYIVWORQ-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 3-((R)-hydroxy(phenyl)methyl)piperidine-1-carboxylate 在 盐酸 、 水 作用下， 以 乙腈 为溶剂， 生成 (R)-phenyl-[(3R)-piperidin-3-yl]methanol
  参考文献：
  名称：

  Design and optimization of renin inhibitors: Orally bioavailable alkyl amines

  摘要：

  Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47 nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.140
• 作为产物：
  描述：

  (3R)-3-[(甲氧基甲基氨基)羰基]-1-哌啶羧酸 1,1-二甲基乙酯 在 (R)-2-甲基-CBS-恶唑硼烷 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 1.66h， 生成 (R)-tert-butyl 3-((R)-hydroxy(phenyl)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] PIPERIDINE AND MORPHOLINE RENIN INHIBITORS
  [FR] PIPÉRIDINE ET MORPHOLINE INHIBITEURS DE LA RÉNINE

  摘要：

  公开号：

  WO2007117560A3

文献信息

• Catalyst-Controlled Diastereoselection in the Hydrogenation of Heterocycloalkyl Ketones
  作者：Masaya Akashi、Noriyoshi Arai、Tsutomu Inoue、Takeshi Ohkuma

  DOI：10.1002/adsc.201100398

  日期：2011.8

  α-Substituted chiral ketones that have small steric and electronic differences around the reaction sites are difficult substrates to reduce with high diastereoselectivity. Metal hydride reduction of 2-(4-benzoylmorpholinyl) phenyl ketone and 3-(1-tert-butoxycarbonylpiperidinyl) phenyl ketone using sodium borohydride, zinc borohydride, and potassium tri-sec-butylborohydride as reducing agents affords

  在反应位点附近具有小的空间和电子差异的α-取代的手性酮是难以以高非对映选择性还原的底物。使用硼氢化钠，硼氢化锌和三仲丁基硼氢化钾作为还原剂，对2-（4-苯甲酰基吗啉基）苯基酮和3-（1-叔丁氧基羰基哌啶基）苯基酮进行金属氢化物还原，可制得顺式和反式醇比例低于80:20。这些酮用的RuCl的催化剂体系的加氢2（BIPHEP）（DMEN）和氢叔在2-丙醇结果丁醇顺选择性≥99：1的醇[BIPHEP = 2,2'-双（二苯基膦基）联苯，DMEN = N，N-二甲基乙二胺]。非对映选择性的显着差异表明该氢化反应中的立体选择主要由催化剂反应场的结构（“催化剂控制的非对映选择性”）调节，而不是由底物的内部立体控制。该化学是通过动态动力学拆分用的RuCl施加到不对称氢化2 - [（小号）-BINAP] [（[R）-DMAPEN] /钾叔-丁氧化物催化剂[BINAP = 2,2'-双（二苯基膦基）-1,1'-联萘基，DMAPEN
• [EN] TREATMENT OF METABOLIC SYNDROME WITH CYCLIC AMIDES<br/>[FR] TRAITEMENT DU SYNDROME MÉTABOLIQUE PAR DES AMIDES CYCLIQUES
  申请人：AMPLA PHARMACEUTICALS INC

  公开号：WO2010120889A1

  公开（公告）日：2010-10-21

  The present application relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are'as defined in the claims. The present application also relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome in an affected mammal by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof.

  本申请涉及公式（I）的化合物或其药用盐，其中变量如权利要求中所定义。本申请还涉及通过给受影响的哺乳动物给予公式（I）的化合物或其药用盐来治疗代谢综合征或与代谢综合征相关的疾病。
• Diaminoalkane Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20090018103A1

  公开（公告）日：2009-01-15

  Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.

  公式I的Diaminoalkanes现已被发现，它们具有口服活性并结合到天冬氨酸蛋白酶以抑制其活性。它们在治疗或改善与天冬氨酸蛋白酶活性升高相关的疾病方面非常有用。本发明还涉及使用公式I化合物治疗或改善需要的天冬氨酸蛋白酶相关疾病的方法，包括向该受体施用公式I化合物的有效量。
• Piperidine and Morpholine Renin Inhibitors
  申请人：Baldwin John J.

  公开号：US20090264432A1

  公开（公告）日：2009-10-22

  Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.

  描述了一些口服的化合物，它们能够结合到肾素并抑制其活性。它们在治疗或改善与肾素活性相关的疾病方面是有用的。同时描述了使用这些化合物治疗或改善受肾素介导的疾病的方法。
• Piperidine and morpholine renin inhibitors
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：US07858624B2

  公开（公告）日：2010-12-28

  Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.

  描述了一些口服活性化合物，它们能够结合到肾素上，从而抑制其活性。它们可用于治疗或缓解与肾素活性相关的疾病。同时，还描述了使用这些化合物治疗或缓解受体内肾素介导的疾病的方法。